This fact is relevant for clinical studies on the use of nimodipine to restore progranulin expression in progranulin mutation carriers who will develop frontotemporal lobe dementia [53], which could be worsened by increased amyloid deposition. This evidence concerns the gene GRN and semantic dementia.